Skytrofa is a long-acting form of somatropin. Somatropin is also called human growth hormone. Skytrofa is also considered a pegylated somatropin product. Pegylated means the medication is attached to ...

COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment ...

The approval was based on data from the phase 3 heiGHt trial, which compared Skytrofa to somatropin in 161 treatment-naïve, prepubertal patients with growth hormone deficiency. Skytrofa ® ...

The approval was based on data from the phase 3 heiGHt trial that assessed Skytrofa in 161 treatment-naïve, prepubertal patients with growth hormone deficiency. The Food and Drug Administration has ...

What Is Skytrofa, and Why Does It Matter? Skytrofa (lonapegsomatropin-tcgd) is a long-acting version of human growth hormone (hGH). It is already approved for children with growth hormone deficiency ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the first once-weekly formulation of somatropin for children with growth hormone deficiency, ...

Shares of Ascendis Pharma A/S ASND rose more than 21% on Aug 26 following approval of its biologics license application (BLA) for Skytrofa (TransConhGH; lonapegsomatropin-tcgd) by the FDA. The BLA ...

SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[1] "We are delighted to have secured TGA ...